MARKET INSIGHTS

The Global Pyrvinium Pamoate market size was valued at USD 22.5 million in 2024. The market is projected to grow from USD 23.8 million in 2025 to reach USD 35.2 million by 2032, exhibiting a CAGR of 5.7% during the forecast period.

Pyrvinium Pamoate is an anthelmintic medication primarily used to treat parasitic worm infections, most notably pinworm (Enterobius vermicularis). It is a cyanine dye that works by inhibiting oxidative phosphorylation in the mitochondria of the parasite, effectively blocking its glucose uptake and leading to its death. While its primary application remains in human and veterinary medicine as an anthelmintic, significant research is being conducted into its potential as an anti‑cancer agent due to its ability to inhibit the Wnt signaling pathway, which is implicated in various cancers.

The market growth is primarily driven by the persistent global prevalence of intestinal parasitic infections, particularly in regions with developing healthcare infrastructure and crowded living conditions. The World Health Organization estimates that over 1.5 billion people, or 24% of the world’s population, are infected with soil‑transmitted helminths, creating a consistent demand for effective treatments. Furthermore, the ongoing exploration of Pyrvinium Pamoate’s repurposing in oncology is generating new interest and investment in the compound. Key manufacturers, such as Dideu Group and Changzhou Yuanda Pharmaceutical Chemical, are focusing on producing high‑purity grades (Above 98% and Above 99%) to meet both pharmaceutical and research‑grade application demands.

Global Pyrvinium Pamoate Market – View in Detailed Research Report

Top 10 Companies in the Global Pyrvinium Pamoate Market (2026)

1. Dideu Group (China)

   Headquarters: Shanghai, China
   Key Offering: High‑purity Pyrvinium Pamoate API (Above 99%) for anthelmintic and research applications

   Dideu Group leverages its extensive chemical synthesis capabilities to supply the most stringent purity grades demanded by pharmaceutical manufacturers. Its production lines are certified under GMP and ISO 9001, ensuring consistent quality for both prescription drugs and preclinical studies.

   Sustainability & Growth Initiatives:

   • Investment in green chemistry to reduce solvent usage.
   • Partnerships with academic institutions for drug repurposing trials.
   • Expansion of export capacity to meet rising demand in Asia‑Pacific and Europe.

2. Changzhou Yuanda Pharmaceutical Chemical (China)

   Headquarters: Changzhou, China
   Key Offering: Pyrvinium Pamoate reagent‑grade (Above 98%) and specialty chemicals

   Yuanda focuses on supplying high‑purity reagents for research laboratories worldwide. Its strategic location near major chemical hubs reduces logistics costs and supports rapid delivery to global clients.

   Sustainability & Growth Initiatives:

   • Adoption of renewable energy in manufacturing plants.
   • Collaboration with biotech firms to explore anticancer applications.
   • Continuous improvement of purification processes to lower impurities.

3. Hairui (China)

   Headquarters: Shenzhen, China
   Key Offering: Custom synthesis of Pyrvinium Pamoate derivatives for research purposes

   Hairui’s flexible contract‑manufacturing model allows it to serve niche academic projects and small‑scale pharmaceutical startups, positioning it as a key player in the research‑grade market.

   Sustainability & Growth Initiatives:

   • Implementation of waste‑reduction protocols.
   • Development of a digital platform for order tracking and quality reporting.
   • Engagement with regional universities to co‑develop new analogues.

4. Norna Group (China)

   Headquarters: Tianjin, China
   Key Offering: Bulk API production and formulation services for anthelmintic drugs

   Norna combines large‑scale synthesis with formulation expertise, enabling it to provide end‑to‑end solutions from API to finished dosage forms.

   Sustainability & Growth Initiatives:

   • Investment in energy‑efficient reactors.
   • Collaboration with public health agencies to support mass drug administration.
   • Expansion of R&D capabilities to explore combination therapies.

5. Cayman Chemical (USA)

   Headquarters: Boca Raton, Florida, USA
   Key Offering: Research‑grade Pyrvinium Pamoate and related cyanine dyes

   As a leading supplier of specialty chemicals, Cayman Chemical supplies reagents to universities, contract research organisations, and pharmaceutical companies across North America and Europe.

   Sustainability & Growth Initiatives:

   • Use of recycled solvents in synthesis.
   • Partnerships with biotech firms for early‑stage oncology studies.
   • Robust quality‑management system to ensure batch consistency.

6. GSK (United Kingdom)

   Headquarters: London, United Kingdom
   Key Offering: Investigational drug development of Pyrvinium Pamoate for colorectal cancer

   GSK’s oncology division is actively pursuing clinical trials that evaluate the drug’s Wnt‑inhibition properties, aiming to reposition the compound as a novel anticancer therapy.

   Sustainability & Growth Initiatives:

   • Investment in precision‑medicine platforms.
   • Commitment to reducing carbon footprint across its global operations.
   • Strategic alliances with academic research centres.

7. Pfizer (United States)

   Headquarters: New York, USA
   Key Offering: Clinical development and supply of Pyrvinium Pamoate for parasitic disease trials

   Pfizer’s global research network supports large‑scale parasitic disease studies, leveraging its supply chain to deliver high‑purity APIs to clinical sites.

   Sustainability & Growth Initiatives:

   • Implementation of digital tracking of raw‑material sourcing.
   • Collaborations with global health NGOs to expand access.
   • Investment in next‑generation manufacturing technologies.

8. Bayer (Germany)

   Headquarters: Leverkusen, Germany
   Key Offering: Development of fixed‑dose combination therapies involving Pyrvinium Pamoate

   Bayer is exploring synergy with other anthelmintics to address drug resistance, aiming to deliver combination products for parasitic infections.

   Sustainability & Growth Initiatives:

   • Adoption of circular‑economy principles in production.
   • Partnerships with regional health ministries.
   • Investment in advanced purification technologies.

9. Merck (Germany)

   Headquarters: Darmstadt, Germany
   Key Offering: Research support for Pyrvinium Pamoate’s anticancer potential

   Merck’s research arm collaborates with academic partners to validate preclinical models, supporting the drug’s repositioning pathway.

   Sustainability & Growth Initiatives:

   • Use of renewable energy in labs.
   • Open‑science data sharing initiatives.
   • Focus on reducing waste in synthesis.

10. Sanofi (France)

    Headquarters: Paris, France
    Key Offering: Development of anthelmintic formulations and distribution network expansion

    Sanofi’s extensive pharmaceutical portfolio and distribution network position it to scale up Pyrvinium Pamoate availability in emerging markets.

    Sustainability & Growth Initiatives:

    • Commitment to achieving net‑zero emissions by 2040.
    • Strategic sourcing from sustainable suppliers.
    • Investment in health‑tech platforms for remote monitoring.

Download FREE Sample Report

Get Full Report

Outlook

The Global Pyrvinium Pamoate market is poised to maintain steady growth through 2034, driven by the dual forces of persistent parasitic disease burden and the acceleration of drug‑repurposing programmes. The expansion of high‑purity manufacturing capabilities across Asia‑Pacific and the entry of major pharmaceutical players into oncology trials will create a more diversified demand profile.

Future Trends

• Repurposing initiatives targeting colorectal and pancreatic cancers are expected to unlock new revenue streams.
• Advances in micro‑encapsulation and sustained‑release technologies could improve patient compliance in pediatric and veterinary segments.
• Digital supply‑chain platforms will enable real‑time tracking of API quality, supporting regulatory compliance and market transparency.
• Strategic alliances between chemical manufacturers and public‑health agencies will accelerate access to essential medicines in low‑income regions.